Optibrium, a developer of software for drug discovery, has appointed Dr Tim Hohm as Director of Commercial Strategy and Business Development. Hohm will be responsible for leading the company’s commercial strategy and sales processes, with a focus on further expanding Optibrium’s global customer base.
In addition to managing existing customer relationships and new business opportunities, Hohm’s role will involve market and customer insight in relation to the company’s StarDrop and Augmented Chemistry products and services, helping to guide the continued development of Optibrium’s in silico drug discovery technologies and artificial intelligence services.
Hohm joins Optibrium from Novo Nordisk where he held a position as Senior Competitive Intelligence Manager. His role at Novo Nordisk covered digital health and delivery technology with responsibilities including strategy development, defining target product profiles and building business cases for pipeline projects and external opportunities.
Hohm has a PhD in Computational Biology from ETH Zurich and research experience with optimisation heuristics and quantitative modelling of gene regulatory networks. His natural sciences background is complemented with an MBA from the internationally recognised Copenhagen Business School.
Dr Matthew Segall, Optibrium’s CEO, said: “Tim’s background in business strategy, and combined experience in the drug development value chain, pharmaceutical research and development and computational sciences, will be invaluable in attaining our ambitious expansion plans and sustained commercial growth. ”
Hohm said: “I am pleased to be joining Optibrium at this exciting time, following the launch of the Company’s StarDrop 6.6 software and recent introduction of the new Augmented Chemistry platform.”
